ArticleEpidemiology and infection2026
Cytomegalovirus seroprevalence and seroconversion in the Irish blood donor population.
Article in Epidemiology and infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytomegalovirus (CMV) is a ubiquitous virus with significant public health implications, including severe morbidity and mortality in neonates and immunosuppressed individuals. Substantial variation in CMV prevalence has been reported globally, and local epidemiological data are important to inform public health interventions. In this study, we estimated CMV seroprevalence and seroconversion rates among blood donors to provide baseline data on CMV epidemiology in Ireland. Seroprevalence was estimated in 74,821 donors, and seroconversion rates were calculated among returning donors, with associations assessed by demographic and geographical factors. Overall CMV seroprevalence in 2020 was 26.0% [95%CI: 25.7-26.3]. Female donors had higher odds of seropositivity than males (adjusted OR: 1.38, [95%CI: 1.34-1.43]). Among first-time donors, CMV seroprevalence was 23.82% [95% CI; 22.79-24.86], whereas within Sample Only New Donors (SOND), who are first-time donors born outside of Ireland and the UK, the seroprevalence was significantly higher, at 46.49% [95% CI; 40.41-52.98, p < 0.001]. The estimated annual seroconversion rate was 0.76% [95% CI: 0.68-0.85], with CMV DNA detected in 6.5% of seroconverters. These findings highlight a low CMV seroprevalence in Ireland, suggesting increased susceptibility to primary infection. Analysis of blood donor CMV data is a useful epidemiological tool to assess population-level risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.